COVID-19時代のアレルギー性呼吸器疾患ケア：EUFOREAの声明

Allergic respiratory disease care in the COVID-19 era: a EUFOREA statement.

• Scadding Glenis K
• Hellings Peter W
• Bachert Claus
• Bjermer Leif
• Diamant Zuzana
• Gevaert Philippe
• Kjeldsen Anette
• Kleine-Tebbe Jorge
• Klimek Ludger
• Muraro Antonella
• Roberts Graham
• Steinsvik Andreas
• Wagenmann Martin
• Wahn Ulrik

抄録

2020年の春と夏は、花粉症に苦しむ人々のケアの課題がCOVID-19パンデミックと重なるという点でユニークである。アレルギー性鼻炎（AR）と喘息の最適なケアを可能にし、くしゃみ、鼻漏、咳を介したコロナウイルスの伝播を防ぐためには、いくつかの考慮事項が重要である。アレルギー性気道疾患とAITに関するEUFOREAの専門家チームによる勧告のコンパクトな概要は、上記のキーワードに関連したCOVID-19の最新文献の調査と、関係する専門家の臨床経験の共有に基づいています。ARとコロナウイルス感染症の類似点と相違点、アレルゲン特異的免疫療法、AITに関するガイダンスを含むCOVID-19時代のアレルギー性疾患ケアのための具体的な推奨事項を扱っています。

Spring and Summer 2020 are unique in that the challenges of care for those suffering from pollen allergy coincide with the COVID-19 pandemic. Several considerations are important to allow optimal care of allergic rhinitis (AR) and asthma and hence prevention of coronavirus spread through sneezing, rhinorrhoea and coughing. This compact overview of recommendations by the EUFOREA expert teams on allergic airway diseases and AIT is based on investigation of the current COVID-19 literature in association with the key words above and shared clinical experience of the experts involved. It deals with similarities and differences between AR and coronavirus infection, specific recommendations for allergic disease care in the COVID-19 era, including guidance on allergen specific immunotherapy, AIT.

Crown Copyright © 2020 Published by Elsevier Inc. on behalf of World Allergy Organization.